Archives

Is medical device HTA really a pain?

Health Technology Assessment (HTA) of medical devices is perceived in Europe and the developed world as an integral part of market access activities and, consequently, the advocacy of the real value of innovation in healthcare. Rigorous scientific analyses demonstrating the value of innovation for patients and society should not be perceived a burden for manufacturers […]

Read More

Aggregation of data reduces its scientific value

Aggregation is considered the least wanted way of anonymization for several reasons, primarily due to its limitations in providing detailed and granular insights from the data. While aggregation offers privacy benefits by grouping data into broader categories, it can significantly reduce data utility and hinder the potential for meaningful analysis. Here are some reasons why […]

Read More

Anonymization of Health Data: Safeguarding Privacy in Administrative Claim Data

In today’s data-driven world, the use of health data has become a cornerstone of scientific research and healthcare decision-making. Administrative claim data, which contains a wealth of information about patients’ medical treatments and expenditures, is a valuable resource for understanding healthcare trends and improving patient outcomes. However, releasing such data without proper safeguards can jeopardize […]

Read More

Patient journey analysis

The oncology patient pathway includes a series of steps that a cancer patient goes through: from diagnosis to treatment and beyond. It considers all aspects of care including diagnoses, treatment planning, care delivery, follow-up care, and end-of-life care. The cancer patient journey is ideally designed to provide comprehensive and coordinated care for cancer patients and […]

Read More

Another significant victory on the way to transparent healthcare

The plaintiff unsuccessfully requested a statistical overview of the number of people who died for individual time periods from various causes after the ÚZIS. These questions may undoubtedly be a matter of legitimate public interest and therefore part of the public domain. According to the Constitutional Court (even taking into account the established jurisprudence of […]

Read More

Societal perspective in economic evaluation in healthcare

Three perspectives are most commonly used in economic evaluations in the healthcare sector: (1) the payer perspective, which includes only the costs and utility of a particular party such as the patient, employer, or insurer; (2) the health care perspective, which includes only the costs and utility within the health care sector; and last but […]

Read More

Performance-based managed entry agreements

Managed entry agreements (MEA) are arrangements that address uncertainty about the performance of technologies (mainly medicines) and simultaneously manage their adoption in order to maximize their effective use, or limit their budget impact. Basically, MEAs can be understood as a tool that gives patients an access to new medicines, while the risk of uncertain effectiveness […]

Read More